title: M1 muscarinic mechanisms regulate intestinal-phase gallbladder physiology in humans.
abstract: The contribution of muscarinic receptor subtypes to biliary control mechanisms is unclear. We investigated stimulated gallbladder function and release of associated hormones during M1-receptor blockade. Following a double-blind, randomized, crossover protocol, healthy volunteers each received placebo and telenzepine, a selective M1-receptor antagonist, as 2-h background infusion. Gallbladder contraction (by ultrasonography), bilirubin output, and release of cholecystokinin (CCK) and pancreatic polypeptide (PP) were assessed during increasing doses of endogenous (intraduodenal nutrient) and exogenous (hormonal) stimulation. All parameters were stimulated in a dose-dependent manner on placebo days. Contractile and secretory responses to low-dose caerulein (CCK analogue) were inhibited by 60-80% under telezepine, whereas high-dose (supraphysiological) stimulation overrode this effect. Similar inhibition was achieved during nutrient stimulation. CCK plasma levels rose during endogenous and exogenous stimulation but were unaffected by M1 blockade, whereas stimulated PP release was completely inhibited (> 100% decrease), reflecting suppressed vagal tone. Selective M1-receptor blockade inhibits the physiological response of the gallbladder in humans; this effect cannot be attributed to suppressed CCK release. Our findings support the hypothesis that CCK acts at the gallbladder via cholinergic nerves under physiological conditions. Viewed with our previous observations, nonselective antagonism of biliary function by atropine is primarily mediated through M1 muscarinic pathways.
authors.affiliation: Genesee Hospital, University of Rochester, New York 14607, USA.
authors.forename: D K
authors.initials: DK
authors.lastname: Nelson
authors.forename: B
authors.initials: B
authors.lastname: Glasbrenner
authors.forename: G
authors.initials: G
authors.lastname: Dahmen
authors.forename: R L
authors.initials: RL
authors.lastname: Riepl
authors.forename: P
authors.initials: P
authors.lastname: Malfertheiner
authors.forename: G
authors.initials: G
authors.lastname: Adler
mesh_terms: D000328:Adult; D001663:Bilirubin / Q000378:metabolism; D002108:Ceruletide / Q000494:pharmacology; D002766:Cholecystokinin / Q000378:metabolism; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004386:Duodenum / Q000502:physiology*; D005704:Gallbladder / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects / Q000502:physiology; D010191:Pancreatic Polypeptide / Q000494:pharmacology*; D010276:Parasympatholytics / Q000494:pharmacology*; D010890:Pirenzepine / Q000031:analogs & derivatives* / Q000494:pharmacology; D010919:Placebos; D043585:Receptor, Muscarinic M2; D011976:Receptors, Muscarinic / Q000187:drug effects / Q000502:physiology*
chemical_list: D010276:Parasympatholytics; D010919:Placebos; D043585:Receptor, Muscarinic M2; D011976:Receptors, Muscarinic; C046338:telenzepine; D010890:Pirenzepine; D010191:Pancreatic Polypeptide; D002108:Ceruletide; D002766:Cholecystokinin; D001663:Bilirubin